drugset / Trial / NCT01465282

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

NCT01465282

Phase 2 Completed 160 enrolled Creabilis SA
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.

Timeline

Start
2011-12
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CT327 Unknown 0.05 %
Subject CT327 Unknown 0.1 %
Subject CT327 Unknown 0.5 %

Indications